Search
Home
About Us
Leadership and Staff
Technologies
Publications
Resources
Project Initiation: Assay Glossary
BioInformatics : Analysis Pipelines
Education and Outreach
Reading Clinical Reports
Services
Genomics Services
Project Initiation
Contact Us
Search
Home
About Us
Leadership and Staff
Technologies
Publications
Resources
Project Initiation: Assay Glossary
BioInformatics : Analysis Pipelines
Education and Outreach
Reading Clinical Reports
Services
Genomics Services
Project Initiation
Contact Us
Tags | 2023
Home
»
2023
Publications
Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
2023
publications
Publications
Transcriptomic changes in liver transplant recipients with non-alcoholic steatohepatitis indicate dysregulation of wound healing
2023
publications
Publications
RBFOX2 Modulates a Metastatic Signature of Alternative Splicing in Pancreatic Cancer
2023
publications
Publications
Coronavirus disease 2019 (COVID-19) outbreak on an in-patient medical unit associated with unrecognized exposures in common areas—Epidemiological and whole-genome sequencing investigation
2023
publications
Publications
Integrated, Longitudinal Analysis of Cell-free DNA in Uveal Melanoma
2023
publications
Publications
A polygenic two-hit hypothesis for prostate cancer
2023
publications
Publications
In-depth characterization of intratumoral heterogeneity in refractory B-cell non-Hodgkin lymphoma through the lens of a Research Autopsy Program
2023
publications
Publications
Molecular characterisation of pancreatic ductal adenocarcinoma with NTRK fusions and review of the literature
2023
publications
Categories
Education
Publications
Categories
Education
Publications
Tags
2020
2021
2022
2023
2024
cbw
education
publications
Tags
2020
2021
2022
2023
2024
cbw
education
publications
Top Posts
Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples
Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair—Proficient Colorectal or Pancreatic Cancer
Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity
Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA.
Top Posts
Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples
Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair—Proficient Colorectal or Pancreatic Cancer
Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity
Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA.